Among other things, the need for extra funding for a phase III study with Diamyd Medical's diabetes vaccine candidate has made the Swedish company carry out a directed share issue.
The equity issuance, which has raised USD 17.5m (DKK 110m) for the company, targeted several institutional investors as well as qualified private investors in Sweden.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.